VolitionRx Raises $1.2M for Clinical Trials of Cancer Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Singapore-based VolitionRx today announced it has raised about $1.2 million, which will be used to support further development of its diagnostic test kits.

The firm, which is developing blood-based diagnostic tests for cancer using its nucleosomes technology, raised about $1 million through a private placement of 582,510 shares for $1.75 per share. Each share entitles the holder to one share of common stock and one warrant to purchase half a share of common stock at $2.60 per share, valid for four years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.